<p>马萨诸塞州沃尔瑟姆和都柏林，2025 年 12 月 5 日（全球新闻稿）—— Mural Oncology plc（纳斯达克：MURA）（“ <strong>Mural</strong>”）宣布，根据 2014 年公司法第 9 部分第 1 章的安排计划（“ <strong>计划</strong>”），XRA 5 Corp.（“ <strong>子公司</strong>”），XOMA Royalty Corporation（纳斯达克：XOMA）（“ <strong>XOMA Royalty</strong>”）的全资子公司，将收购 Mural 的全部已发行和待发行股份，计划于 2025 年 12 月 5 日（“ <strong>生效日期</strong>”）生效。</p>
<p>根据计划条款，子公司向计划股东支付的现金对价的支票分发和 DTC 参与者账户的记账预计将在生效日期后尽快开始，DTC 参与者账户预计将被记账，支票分发预计将尽快完成。根据爱尔兰收购规则的要求，子公司向计划股东支付的所有对价将在 2025 年 12 月 19 日之前分发完毕。</p>
<p>Mural 股份在纳斯达克全球市场的交易取消自 2025 年 12 月 4 日美国东部时间晚上 8:00 起生效。</p>
<p>除非另有定义，本公告中使用但未定义的专有名词与 Mural 于 2025 年 9 月 23 日发布的关于收购的最终代理声明中所赋予的含义相同，该声明也构成了根据爱尔兰法律的计划通函。</p>
<p>不得在任何法律或法规禁止的司法管辖区内全部或部分发布、出版或分发本公告。</p>
<p>立即发布</p>
<p><strong>咨询</strong></p>
<p>Mural Oncology plc</p>
<p>ir@muraloncology.com</p>
<p>Lucid Capital Markets, LLC（Mural 的财务顾问）</p>
<p>570 Lexington Ave, 40 楼</p>
<p>纽约，NY 10022</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本公告中关于非历史事实事项的声明为 1995 年私人证券诉讼改革法案所定义的 “前瞻性声明”，涉及 Mural、XOMA Royalty 或子公司。前瞻性声明旨在通过 “预期”、“目标”、“期待”、“估计”、“打算”、“计划”、“相信”、“将”、“可能”、“会”、“可以” 或 “应该” 或其他类似含义的词语或其否定形式来识别。前瞻性声明包括但不限于关于子公司向计划股东支付对价的预计时间以及 Mural 股份在纳斯达克全球市场交易取消的预计时间的声明。</p>
<p>这些前瞻性声明涉及已知和未知的风险、不确定性及其他因素，可能导致实际结果与这些前瞻性声明所表达或暗示的结果存在重大差异。可能导致实际结果与预期不同的风险和不确定性包括：与 Mural 业务相关的风险和不确定性，包括在 Mural 最近提交的 10-K 表格年度报告、向美国证券交易委员会（“SEC”）提交的 10-Q 表格季度报告以及 2025 年 9 月 23 日向 SEC 提交的最终代理声明中所描述的风险和不确定性，以及与 XOMA Royalty 相关的其他潜在风险和不确定性，包括在 XOMA Royalty 最近提交的 10-K 表格年度报告、10-Q 表格季度报告及其其他向 SEC 提交的文件中更详细描述的风险和不确定性。您被警告不要对这些前瞻性声明过于依赖，这些声明仅在作出时有效。所有后续口头或书面的前瞻性声明，归因于 Mural、XOMA Royalty 或子公司或其代表的任何人，均完全受上述警示声明的限制。Mural、XOMA Royalty 或子公司均不承担更新或修订本公告中包含的前瞻性声明的任何义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。</p>
<p><strong>爱尔兰收购规则要求的声明</strong></p>
<p>Mural 的董事会对本公告中包含的信息承担责任。根据 Mural 董事会的最佳知识和信念（董事会已采取一切合理的注意以确保情况如此），本公告中包含的信息符合事实，并未遗漏任何可能影响该信息重要性的内容。</p>
<p>Lucid 在美国由 SEC 和金融业监管局（“ <strong>FINRA</strong>”）授权和监管，作为 Mural 的财务顾问，仅为 Mural 提供服务，而不为其他任何人提供与本公告主题相关的服务，并且不会将任何其他人视为其在本公告事项中的客户，也不会对除 Mural 以外的任何人提供 Lucid 或其附属公司的客户所享有的保护，也不会就本公告中提到的任何事项提供建议。Lucid 及其任何子公司、附属公司或分支机构对任何非 Lucid 客户在本公告中涉及的事项、任何声明或其他事项或安排不承担或接受任何责任（无论是直接、间接、后果性，无论是合同、侵权、法定或其他方式）。</p>
<p>Davy Corporate Finance 在爱尔兰由爱尔兰中央银行授权和监管，专门为 XOMA Royalty 提供服务，与本公告中提及的事项相关，不对除 XOMA Royalty 以外的任何人负责提供 Davy Corporate Finance 客户所享有的保护或提供与本公告中提及的事项相关的建议。</p>
<p>Wilmer Cutler Pickering Hale and Dorr LLP 和 Arthur Cox LLP 分别作为 Mural 的美国和爱尔兰法律顾问，而 Gibson, Dunn &amp; Crutcher LLP 和 Mason Hayes &amp; Curran LLP 则分别作为 XOMA Royalty 和 Sub 的美国和爱尔兰法律顾问。</p>
<p><strong>一般信息</strong></p>
<p>本公告的发布、公布或分发在某些司法管辖区可能受到该等司法管辖区法律的限制。因此，本公告及与收购相关的所有其他文件的副本不得在任何此类受限司法管辖区内或向其发布、公布、邮寄或以其他方式转发、分发或发送。接收此类文件的人员（包括但不限于提名人、受托人和保管人）应遵守这些限制。未能遵守可能构成对任何此类司法管辖区证券法的违反。在适用法律允许的最大范围内，Mural、XOMA Royalty 和 Sub 对任何人违反任何此类限制不承担任何责任或义务。</p>
<p><strong>网站发布</strong></p>
<p>根据爱尔兰收购规则第 26.1 条，本公告的副本将在 Mural 的网站 https://ir.muraloncology.com/ 上发布，最迟在本公告发布后的工作日中午 12:00（美国东部时间）之前。公告中提及的网站内容以及从该网站超链接访问的任何其他网站的内容均不构成本公告的一部分。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UXdPQ00zTXpBM05qSXhJekl5TmpJek5ETT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UXdPQ00zTXpBM05qSXhJekl5TmpJek5ETT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png"/></p>

MURA

<p>Mural Oncology plc 宣布其安排计划的有效性，这导致其被 XRA 5 Corp. 收购，后者是 XOMA Royalty Corporation 的子公司。此次收购涉及 Mural 的全部已发行股本。预计现金对价的分配将很快开始，并将在 2025 年 12 月 19 日之前完成。Mural 的股票已于 2025 年 12 月 4 日从纳斯达克全球市场退市。前瞻性声明提醒潜在的风险和不确定性</p>

<p>WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ <strong>Mural</strong>”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “ <strong>Scheme</strong>”) pursuant to which XRA 5 Corp. (“ <strong>Sub</strong>”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“ <strong>XOMA Royalty</strong>”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “ <strong>Effective Date</strong>”).</p>
<div class="lb-trans"><p>马萨诸塞州沃尔瑟姆和都柏林，2025 年 12 月 5 日（全球新闻稿）—— Mural Oncology plc（纳斯达克：MURA）（“ <strong>Mural</strong>”）宣布，根据 2014 年公司法第 9 部分第 1 章的安排计划（“ <strong>计划</strong>”），XRA 5 Corp.（“ <strong>子公司</strong>”），XOMA Royalty Corporation（纳斯达克：XOMA）（“ <strong>XOMA Royalty</strong>”）的全资子公司，将收购 Mural 的全部已发行和待发行股份，计划于 2025 年 12 月 5 日（“ <strong>生效日期</strong>”）生效。</p>
</div><p>Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.</p>
<div class="lb-trans"><p>根据计划条款，子公司向计划股东支付的现金对价的支票分发和 DTC 参与者账户的记账预计将在生效日期后尽快开始，DTC 参与者账户预计将被记账，支票分发预计将尽快完成。根据爱尔兰收购规则的要求，子公司向计划股东支付的所有对价将在 2025 年 12 月 19 日之前分发完毕。</p>
</div><p>Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market occurred with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.</p>
<div class="lb-trans"><p>Mural 股份在纳斯达克全球市场的交易取消自 2025 年 12 月 4 日美国东部时间晚上 8:00 起生效。</p>
</div><p>Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law.</p>
<div class="lb-trans"><p>除非另有定义，本公告中使用但未定义的专有名词与 Mural 于 2025 年 9 月 23 日发布的关于收购的最终代理声明中所赋予的含义相同，该声明也构成了根据爱尔兰法律的计划通函。</p>
</div><p>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION</p>
<div class="lb-trans"><p>不得在任何法律或法规禁止的司法管辖区内全部或部分发布、出版或分发本公告。</p>
</div><p>FOR IMMEDIATE RELEASE</p>
<div class="lb-trans"><p>立即发布</p>
</div><p><strong>Enquiries</strong></p>
<div class="lb-trans"><p><strong>咨询</strong></p>
</div><p>Mural Oncology plc</p>
<div class="lb-trans"><p>Mural Oncology plc</p>
</div><p>ir@muraloncology.com</p>
<div class="lb-trans"><p>ir@muraloncology.com</p>
</div><p>Lucid Capital Markets, LLC (Financial Adviser to Mural)</p>
<div class="lb-trans"><p>Lucid Capital Markets, LLC（Mural 的财务顾问）</p>
</div><p>570 Lexington Ave, 40th Floor</p>
<div class="lb-trans"><p>570 Lexington Ave, 40 楼</p>
</div><p>New York, NY 10022</p>
<div class="lb-trans"><p>纽约，NY 10022</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>Statements contained in this announcement regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should” or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding the expected timing of the payment of the consideration paid by Sub to Scheme Shareholders and the expected timing of the cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market.</p>
<div class="lb-trans"><p>本公告中关于非历史事实事项的声明为 1995 年私人证券诉讼改革法案所定义的 “前瞻性声明”，涉及 Mural、XOMA Royalty 或子公司。前瞻性声明旨在通过 “预期”、“目标”、“期待”、“估计”、“打算”、“计划”、“相信”、“将”、“可能”、“会”、“可以” 或 “应该” 或其他类似含义的词语或其否定形式来识别。前瞻性声明包括但不限于关于子公司向计划股东支付对价的预计时间以及 Mural 股份在纳斯达克全球市场交易取消的预计时间的声明。</p>
</div><p>These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: risks and uncertainties pertaining to Mural’s business, including those described in Mural’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) and definitive proxy statement filed with the SEC on 23 September 2025, as well as Mural’s subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.</p>
<div class="lb-trans"><p>这些前瞻性声明涉及已知和未知的风险、不确定性及其他因素，可能导致实际结果与这些前瞻性声明所表达或暗示的结果存在重大差异。可能导致实际结果与预期不同的风险和不确定性包括：与 Mural 业务相关的风险和不确定性，包括在 Mural 最近提交的 10-K 表格年度报告、向美国证券交易委员会（“SEC”）提交的 10-Q 表格季度报告以及 2025 年 9 月 23 日向 SEC 提交的最终代理声明中所描述的风险和不确定性，以及与 XOMA Royalty 相关的其他潜在风险和不确定性，包括在 XOMA Royalty 最近提交的 10-K 表格年度报告、10-Q 表格季度报告及其其他向 SEC 提交的文件中更详细描述的风险和不确定性。您被警告不要对这些前瞻性声明过于依赖，这些声明仅在作出时有效。所有后续口头或书面的前瞻性声明，归因于 Mural、XOMA Royalty 或子公司或其代表的任何人，均完全受上述警示声明的限制。Mural、XOMA Royalty 或子公司均不承担更新或修订本公告中包含的前瞻性声明的任何义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。</p>
</div><p><strong>Statements Required by the Irish Takeover Rules</strong></p>
<div class="lb-trans"><p><strong>爱尔兰收购规则要求的声明</strong></p>
</div><p>The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.</p>
<div class="lb-trans"><p>Mural 的董事会对本公告中包含的信息承担责任。根据 Mural 董事会的最佳知识和信念（董事会已采取一切合理的注意以确保情况如此），本公告中包含的信息符合事实，并未遗漏任何可能影响该信息重要性的内容。</p>
</div><p>Lucid, which is authorized and regulated by the SEC and the Financial Industry Regulatory Authority (“ <strong>FINRA</strong>”) in the United States, is acting as financial adviser exclusively for Mural and for no one else in connection with the subject matter of this Announcement and will not regard any other person as its client in relation to the matters in this Announcement and will not be responsible to anyone other than Mural for providing the protections afforded to clients of Lucid or its affiliates, nor for providing advice in relation to any matter referred to in this Announcement. Neither Lucid nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lucid in relation to the matters in this Announcement, any statement or other matter or arrangement referred to herein or otherwise.</p>
<div class="lb-trans"><p>Lucid 在美国由 SEC 和金融业监管局（“ <strong>FINRA</strong>”）授权和监管，作为 Mural 的财务顾问，仅为 Mural 提供服务，而不为其他任何人提供与本公告主题相关的服务，并且不会将任何其他人视为其在本公告事项中的客户，也不会对除 Mural 以外的任何人提供 Lucid 或其附属公司的客户所享有的保护，也不会就本公告中提到的任何事项提供建议。Lucid 及其任何子公司、附属公司或分支机构对任何非 Lucid 客户在本公告中涉及的事项、任何声明或其他事项或安排不承担或接受任何责任（无论是直接、间接、后果性，无论是合同、侵权、法定或其他方式）。</p>
</div><p>Davy Corporate Finance, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance or for providing advice in connection with the matters referred to in this Announcement.</p>
<div class="lb-trans"><p>Davy Corporate Finance 在爱尔兰由爱尔兰中央银行授权和监管，专门为 XOMA Royalty 提供服务，与本公告中提及的事项相关，不对除 XOMA Royalty 以外的任何人负责提供 Davy Corporate Finance 客户所享有的保护或提供与本公告中提及的事项相关的建议。</p>
</div><p>Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP are acting as legal advisers on U.S. and Irish law matters respectively to Mural, and Gibson, Dunn &amp; Crutcher LLP and Mason Hayes &amp; Curran LLP are acting as legal advisers on U.S. and Irish law matters respectively to XOMA Royalty and Sub.</p>
<div class="lb-trans"><p>Wilmer Cutler Pickering Hale and Dorr LLP 和 Arthur Cox LLP 分别作为 Mural 的美国和爱尔兰法律顾问，而 Gibson, Dunn &amp; Crutcher LLP 和 Mason Hayes &amp; Curran LLP 则分别作为 XOMA Royalty 和 Sub 的美国和爱尔兰法律顾问。</p>
</div><p><strong>General</strong></p>
<div class="lb-trans"><p><strong>一般信息</strong></p>
</div><p>The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.</p>
<div class="lb-trans"><p>本公告的发布、公布或分发在某些司法管辖区可能受到该等司法管辖区法律的限制。因此，本公告及与收购相关的所有其他文件的副本不得在任何此类受限司法管辖区内或向其发布、公布、邮寄或以其他方式转发、分发或发送。接收此类文件的人员（包括但不限于提名人、受托人和保管人）应遵守这些限制。未能遵守可能构成对任何此类司法管辖区证券法的违反。在适用法律允许的最大范围内，Mural、XOMA Royalty 和 Sub 对任何人违反任何此类限制不承担任何责任或义务。</p>
</div><p><strong>Publication on a Website</strong></p>
<div class="lb-trans"><p><strong>网站发布</strong></p>
</div><p>In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural’s website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.</p>
<div class="lb-trans"><p>根据爱尔兰收购规则第 26.1 条，本公告的副本将在 Mural 的网站 https://ir.muraloncology.com/ 上发布，最迟在本公告发布后的工作日中午 12:00（美国东部时间）之前。公告中提及的网站内容以及从该网站超链接访问的任何其他网站的内容均不构成本公告的一部分。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UXdPQ00zTXpBM05qSXhJekl5TmpJek5ETT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NzQwOCM3MzA3NjIxIzIyNjIzNDM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png"/></p>

Mural Oncology 宣布安排计划的生效及收购的完成 | MURA 股票新闻